John E Shively Selected Research

64Cu-DOTA-trastuzumab

1/2022	Use of 64Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study.
1/2018	Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John E Shively Research Topics

Disease

64	Neoplasms (Cancer) 12/2022 - 09/2002
22	Breast Neoplasms (Breast Cancer) 12/2022 - 01/2004
9	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 12/2003
7	Neoplasm Metastasis (Metastasis) 01/2019 - 12/2003
3	Multiple Myeloma 10/2021 - 01/2013
3	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 03/2005
3	Inflammation (Inflammations) 01/2019 - 01/2012
3	Prostatic Neoplasms (Prostate Cancer) 09/2017 - 01/2013
2	Colonic Neoplasms (Colon Cancer) 01/2022 - 12/2004
2	Liver Neoplasms (Liver Cancer) 01/2022 - 12/2003
2	Hematologic Neoplasms (Hematological Malignancy) 10/2021 - 12/2003
2	Fever (Fevers) 01/2019 - 12/2009
2	Melanoma (Melanoma, Malignant) 01/2018 - 11/2010
2	Carcinogenesis 01/2016 - 05/2011
2	Insulinoma 01/2014 - 08/2011
2	Infections 01/2013 - 10/2010
2	Carcinoma (Carcinomatosis) 09/2011 - 01/2003
1	Experimental Melanoma 01/2022
1	Obesity 01/2022
1	Bacteremia 12/2021
1	Hodgkin Disease (Hodgkin's Disease) 12/2021
1	Insulin Resistance 11/2021
1	Non-alcoholic Fatty Liver Disease 11/2021
1	Myeloid Leukemia (Leukemia, Myelocytic) 12/2019
1	Bites and Stings (Sting) 09/2019
1	Stomach Neoplasms (Stomach Cancer) 01/2019

Drug/Important Bio-Agent (IBA)

33	CEACAM1 ProteinIBA 01/2022 - 01/2003
19	AntibodiesIBA 02/2022 - 12/2003
17	Carcinoembryonic AntigenIBA 12/2022 - 12/2003
11	AntigensIBA 12/2022 - 12/2003
11	Protein Isoforms (Isoforms)IBA 01/2019 - 01/2003
10	Proteins (Proteins, Gene)FDA Link 01/2020 - 03/2005
9	Immunoglobulin FragmentsIBA 09/2017 - 09/2002
7	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 10/2021 - 07/2010
5	ErbB Receptors (EGF Receptor)IBA 01/2022 - 01/2004
4	LipidsIBA 01/2022 - 12/2003
4	Trastuzumab (Herceptin)FDA Link 01/2022 - 09/2005
4	Radioisotopes (Radionuclides)IBA 01/2021 - 12/2003
4	CytokinesIBA 10/2018 - 12/2009
4	Sulfhydryl Compounds (Thiols)IBA 04/2017 - 01/2008
4	Cell Adhesion Molecule-1IBA 01/2014 - 12/2003
4	Monoclonal AntibodiesIBA 03/2013 - 05/2004
3	Chimeric Antigen ReceptorsIBA 10/2021 - 10/2018
3	Amino Acids FDA Link 10/2021 - 12/2003
3	Immunoglobulin G (IgG)IBA 01/2020 - 07/2010
3	human ERBB2 proteinIBA 01/2018 - 08/2010
3	LigandsIBA 04/2017 - 03/2005
3	Cell Adhesion MoleculesIBA 01/2016 - 01/2003
2	Interleukin-2 (IL2)IBA 12/2022 - 01/2020
2	64Cu-DOTA-trastuzumabIBA 01/2022 - 01/2018
2	Neurotensin Receptors (Neurotensin Receptor)IBA 10/2021 - 07/2014
2	Tumor Biomarkers (Tumor Markers)IBA 01/2021 - 09/2005
2	Glycoproteins (Glycoprotein)IBA 01/2021 - 07/2010
2	Neoplasm Antigens (Tumor Antigens)IBA 09/2019 - 01/2006
2	Pharmaceutical PreparationsIBA 09/2017 - 04/2017
2	Lipid NanoparticlesIBA 09/2017 - 04/2017
2	Cysteine (L-Cysteine)FDA Link 04/2017 - 01/2004
2	Fluorouracil (Carac)FDA LinkGeneric 02/2015 - 12/2003
2	Exenatide (Byetta)FDA Link 01/2014 - 08/2011
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 07/2013 - 05/2012
2	Small Interfering RNA (siRNA)IBA 08/2011 - 10/2010
2	RNA Precursors (Precursor, mRNA)IBA 05/2011 - 02/2006
2	Lysine (L-Lysine)FDA Link 04/2011 - 09/2002
2	matrigelIBA 02/2006 - 01/2003
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 03/2005 - 01/2004
1	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 12/2022
1	InterferonsIBA 12/2022
1	RNA (Ribonucleic Acid)IBA 02/2022
1	Muromonab-CD3 (Muromonab CD3)FDA Link 02/2022
1	SolutionsIBA 02/2022
1	Dihydrotachysterol (AT 10)IBA 01/2022
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2022
1	Ado-Trastuzumab EmtansineIBA 01/2022
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022
1	neurotensin (9-13)IBA 10/2021
1	NeurotensinIBA 10/2021
1	Biological ProductsIBA 01/2021
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021
1	daratumumabIBA 01/2021
1	tumor-associated antigen 72IBA 01/2020
1	A 17 (A-17)IBA 01/2020
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2020
1	Immunoconjugates (Immunoconjugate)IBA 01/2020
1	Cell Surface ReceptorsIBA 12/2019
1	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA 01/2019
1	Interleukin-6 (Interleukin 6)IBA 01/2019
1	Fibronectins (Fibronectin)IBA 10/2018

Therapy/Procedure

18	Therapeutics 12/2022 - 12/2003
9	Radioimmunotherapy 12/2021 - 12/2003
5	Drug Therapy (Chemotherapy) 02/2015 - 12/2003
4	Immunotherapy 12/2022 - 09/2019
3	Radiotherapy 10/2021 - 12/2003
2	Islets of Langerhans Transplantation 02/2013 - 08/2011
1	Time-to-Treatment 01/2022
1	Transplantation 01/2022
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2022
1	Catheters 12/2021
1	Cell Transplantation 12/2021
1	Salvage Therapy 12/2021
1	Treatment Delay 01/2021